|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Derivatives | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Deferred financing fees | ||||||||||||||||||||
| Derivatives | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Share-based compensation liability | ||||||||||||||||||||
| Accrued liabilities and other current liabilities | ||||||||||||||||||||
| Operating leases | ||||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||||
| Common stock warrants | ||||||||||||||||||||
| Current derivative liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Debt, net | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Operating leases | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Derivatives | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Commitments and contingencies (Note 9) | ||||||||||||||||||||
| Series A-C convertible preferred stock (Note 10) | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Series B Convertible Preferred Stock | ||||||||||||||||||||
| Series C Convertible Preferred Stock | ||||||||||||||||||||
| Total series A-C convertible preferred stock (Note 10) | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Common stock, $0.0001 par value Authorized: 480.0 million shares at September 30, 2023 and December 31, 2022; Issued and outstanding: 256.5 million shares and 143.5 million shares at September 30, 2023 and December 31, 2022, respectively | ||||||||||||||||||||
| Common stock, $0.0001 par value, 480.0 million authorized: 265.1 million and 264.8 million outstanding, respectively | ||||||||||||||||||||
| Treasury stock: 4.9 million and 4.9 million, respectively, at cost | ||||||||||||||||||||
| Preferred stock, $0.0001 par value, 0.5 million authorized after designation of the convertible preferred stock: none outstanding | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity |
Loading...
